Key facts
- This page summarizes Wilfred E. Jaeger's Form 4 filing for CONCERT PHARMACEUTICALS, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Jun 2021, 08:43.
Wilfred E. Jaeger - 10 Jun 2021 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 10 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2021, 08:43:38 UTC
- Prior SEC filing
- 01 Jun 2021
- Next SEC filing
- 31 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey A. Munsie, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wilfred E. Jaeger filed Form 4 for CONCERT PHARMACEUTICALS, INC. on 11 Jun 2021.
Change
- Previous filing in this sequence was filed on 01 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNCE
transaction
Common Stock
Award
- Transaction value
- Shares
- +5,125
- Change %
- Price
- Shares after
- 5,125
- Date
- 10 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNCE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +10,250
- Change %
- Price
- $0.000000
- Shares after
- 10,250
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,250
- Exercise price
- $4.26
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.
Footnote F2
Not applicable.
Footnote F3
The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022).